

Clinical course and costs of care for Crohn's disease: Ma population-based cohort

Gastroenterology

117, 49-57

DOI: 10.1016/s0016-5085(99)70549-4

Citation Report

#	ARTICLE	IF	CITATIONS
1	Current pharmacotherapy for inflammatory bowel disease. Expert Opinion on Pharmacotherapy, 1999, 1, 3-14.	1.8	2
2	Prevention of Relapse of Crohn's Disease. Inflammatory Bowel Diseases, 2000, 6, 321-328.	1.9	7
3	Timing of Surgery for Enterovesical Fistula in Crohn's Disease: Decision Analysis Using a Time-Dependent Compartment Model. Inflammatory Bowel Diseases, 2000, 6, 280-285.	1.9	9
4	Therapy for Crohn disease. Current Opinion in Gastroenterology, 2000, 16, 318-323.	2.3	6
5	Prevention of relapse of Crohn's disease. Inflammatory Bowel Diseases, 2000, 6, 321-328.	1.9	7
6	Review article: the clinical role of anti-TNF α antibody treatment in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2000, 14, 501-514.	3.7	56
7	The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. European Journal of Clinical Pharmacology, 2000, 56, 353-362.	1.9	47
8	Analyzing hospital costs for patients with inflammatory bowel disease. American Journal of Gastroenterology, 2000, 95, 577-578.	0.4	2
9	Influence of quality of care on quality of life in inflammatory bowel disease (IBD): literature review and studies planned. European Journal of Internal Medicine, 2000, 11, 228-234.	2.2	32
10	A review of standard and novel therapies in Crohn's disease. Expert Opinion on Therapeutic Patents, 2000, 10, 1021-1033.	5.0	0
11	The Cost of Crohn's Disease. BioDrugs, 2000, 14, 331-344.	4.6	2
12	Annual cost of care for Crohn's disease: a payor perspective. American Journal of Gastroenterology, 2000, 95, 1955-1960.	0.4	179
13	Azathioprine for maintenance of remission in Crohn's disease: Benefits outweigh the risk of lymphoma. Gastroenterology, 2000, 118, 1018-1024.	1.3	241
14	The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology, 2001, 121, 255-260.	1.3	1,125
15	Use of anti-tumour necrosis factor agents in inflammatory bowel disease. International Journal of Colorectal Disease, 2001, 16, 1-11.	2.2	52
16	Cause of Death in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2001, 7, 250-255.	1.9	66
17	Clinical Outcome of Crohn's Disease: Analysis According to the Vienna Classification and Clinical Activity. Inflammatory Bowel Diseases, 2001, 7, 306-313.	1.9	133
18	Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study. American Journal of Gastroenterology, 2001, 96, 3348-3355.	0.4	37

#	ARTICLE	IF	CITATIONS
19	Crohn's Disease: Quality of Life and Costs. Clinics in Colon and Rectal Surgery, 2001, 14, 175-180.	1.1	1
21	Research Agenda for Pediatric Gastroenterology, Hepatology and Nutrition: Secretion and Diarrhea: Report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition for the Children's Digestive Health and Nutrition Foundation. Journal of Pediatric Gastroenterology and Nutrition, 2002, 35, S246-S249.	1.8	0
22	Infliximab Decreases Resource Use Among Patients With Crohn's Disease. Journal of Clinical Gastroenterology, 2002, 35, 151-156.	2.2	106
23	Cost of Illness of Crohn's Disease. Pharmacoeconomics, 2002, 20, 639-652.	3.3	73
24	Funding the New Biologics – What Can We Learn from Infliximab? The CCOHTA Report: A Gastroenterologist's Viewpoint. Canadian Journal of Gastroenterology & Hepatology, 2002, 16, 865-868.	1.7	10
25	Funding the New Biologics – CCOHTA Report on the Cost Effectiveness of Infliximab for Crohn's Disease: Pearls and Pitfalls. Canadian Journal of Gastroenterology & Hepatology, 2002, 16, 877-879.	1.7	1
26	Medical management of inflammatory bowel disease in the new millennium. Comprehensive Therapy, 2002, 28, 39-49.	0.2	3
30	The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Alimentary Pharmacology and Therapeutics, 2002, 16, 51-60.	3.7	403
31	The quality of life in patients with Crohn's disease. Alimentary Pharmacology and Therapeutics, 2002, 16, 1603-1609.	3.7	208
32	Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiology and Drug Safety, 2002, 11, 211-218.	1.9	166
33	Crohn's disease: step up or top down therapy. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2003, 17, 131-137.	2.4	61
34	Review article: the data supporting a role for aminosaliclates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2003, 18, 15-21.	3.7	101
35	Challenges in IBD Research: Updating the Scientific Agendas. Inflammatory Bowel Diseases, 2003, 9, 137-153.	1.9	18
36	Infliximab Treatment of Rheumatoid Arthritis and Crohn's Disease. Annals of Pharmacotherapy, 2003, 37, 1256-1265.	1.9	86
37	Burden of illness of Crohn's disease in Spain. Digestive and Liver Disease, 2003, 35, 853-861.	0.9	70
38	Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology, 2003, 125, 320-327.	1.3	306
39	Considerations in the management of steroid-dependent Crohn's disease. Gastroenterology, 2003, 125, 906-910.	1.3	13
40	RDP58, a Novel Immunomodulatory Peptide with Anti-Inflammatory Effects. A Pharmacological Study in Trinitrobenzene Sulphonic Acid Colitis and Crohn Disease. Scandinavian Journal of Gastroenterology, 2003, 38, 526-532.	1.5	20

#	ARTICLE	IF	CITATIONS
41	Insurance problems among inflammatory bowel disease patients: results of a Dutch population based study. <i>Gut</i> , 2003, 52, 358-362.	12.1	15
42	Risk of Early Surgery for Crohn's Disease: Implications for Early Treatment Strategies. <i>American Journal of Gastroenterology</i> , 2003, 98, 2712-2718.	0.4	124
44	Evaluation of a stochastic Markov-chain model for the development of forelimb injuries in Thoroughbred racehorses. <i>American Journal of Veterinary Research</i> , 2003, 64, 328-337.	0.6	17
45	Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. <i>Gut</i> , 2004, 53, 1471-1478.	12.1	269
46	Utilization of Health Care Resources by Individuals with Inflammatory Bowel Disease in the United States: A Profile of Time Since Diagnosis. <i>American Journal of Gastroenterology</i> , 2004, 99, 650-655.	0.4	59
47	Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, 192-199.	2.8	42
48	Aminosalicylates in inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 60-65.	3.7	52
49	Has disease outcome in Crohn's disease changed during the last four decades?. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 483-496.	3.7	103
50	Smoking and Immunomodulators do not Influence the Response or Duration of Response to Infliximab in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 346-351.	1.9	47
51	The Role of Quality of Care in Health-related Quality of Life in Patients with IBD. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 392-398.	1.9	59
52	Crohn's Is Not a 6-Week Disease. <i>Inflammatory Bowel Diseases</i> , 2004, 10, S2-S10.	1.9	30
53	Jejunioileal Crohn's disease: a case-control study. <i>Gastroenterologie Clinique Et Biologique</i> , 2004, 28, 160-166.	0.9	8
54	Crohn's disease over 20 years after diagnosis in a referral population. <i>Gastroenterologie Clinique Et Biologique</i> , 2004, 28, 1233-1239.	0.9	27
55	Chimiothérapie du cancer colorectal dans les maladies inflammatoires intestinales chroniques. Quels sont les médicaments proposés ?. <i>Acta Endoscopica</i> , 2004, 34, 199-213.	0.0	0
56	Gastroesophageal reflux disease: Could intervention in childhood reduce the risk of later complications?. <i>The American Journal of Medicine: Supplement</i> , 2004, 117, 23-29.	1.6	23
58	Crohn's disease patients who quit smoking have a reduced risk of reoperation for recurrence. <i>American Journal of Surgery</i> , 2004, 187, 219-225.	1.8	121
59	Management for severe Crohn's disease: A lifetime cost-utility analysis. <i>International Journal of Technology Assessment in Health Care</i> , 2004, 20, 274-279.	0.5	54
60	Infliximab use in Crohn's disease: impact on health care resources in the UK. <i>European Journal of Gastroenterology and Hepatology</i> , 2005, 17, 1047-1052.	1.6	61

#	ARTICLE	IF	CITATIONS
63	The Case for Using 5-Aminosalicyclates in Crohn's Disease. Inflammatory Bowel Diseases, 2005, 11, 609-612.	1.9	16
64	Clinical features and complications of Crohn's disease. , 2003, , 291-304.		1
65	Pharmacoeconomics and inflammatory bowel disease. , 2003, , 471-480.		0
66	Budesonide for Maintenance of Remission in Patients with Crohn's Disease in Medically Induced Remission: A Predetermined Pooled Analysis of Four Randomized, Double-Blind, Placebo-Controlled Trials. American Journal of Gastroenterology, 2005, 100, 1780-1787.	0.4	124
67	Epidemiology and Precaution 150 Years Before Snow. Epidemiology, 2005, 16, 271-272.	2.7	1
68	Estimating Rare Disease Prevalence From Administrative Hospitalization Databases. Epidemiology, 2005, 16, 270-271.	2.7	15
69	Isolated Ileal Erosions in Patients With Mildly Altered Bowel Habits A Follow-up Study of 28 Patients. American Journal of Clinical Pathology, 2005, 125, 838-846.	0.7	9
70	The costs of human Campylobacter infections and sequelae in the Netherlands: A DALY and cost-of-illness approach. Acta Agriculturae Scandinavica Section C: Food Economics, 2005, 2, 35-51.	0.1	22
71	Economic Implications of Biological Therapies for Crohn's Disease. Pharmacoeconomics, 2005, 23, 875-888.	3.3	26
72	Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology, 2005, 128, 862-869.	1.3	548
73	Early or late guided missile in the treatment of Crohn's disease?. Digestive and Liver Disease, 2005, 37, 973-979.	0.9	13
74	Economics of the Use of Biologics in the Treatment of Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2006, 35, 867-882.	2.2	28
75	Risks and Benefits of Infliximab for the Treatment of Crohn's Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 1017-1024.	4.4	130
76	Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease. Pharmacoeconomics, 2006, 24, 767-781.	3.3	83
77	Health Care Resource Utilization in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 731-743.	4.4	75
78	Step-Up Versus Top-Down: Application of New Biological Agents in Pediatric Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 1094-1096.	4.4	6
79	Cost Analysis and Cost Determinants in a European Inflammatory Bowel Disease Inception Cohort With 10 Years of Follow-up Evaluation. Gastroenterology, 2006, 131, 719-728.	1.3	213
80	Biological Therapy in the Management of Recent-Onset Crohn's Disease. Drugs, 2006, 66, 1431-1439.	10.9	29

#	ARTICLE	IF	CITATIONS
81	Economic burden of inflammatory bowel disease: a UK perspective. Expert Review of Pharmacoeconomics and Outcomes Research, 2006, 6, 471-482.	1.4	27
82	Disease outcome of inflammatory bowel disease patients: General outline of a Europe-wide population-based 10-year clinical follow-up study. Scandinavian Journal of Gastroenterology, 2006, 41, 46-54.	1.5	71
83	Conventional therapy for Crohn's disease. World Journal of Gastroenterology, 2006, 12, 4794.	3.3	16
84	Factors associated with disease evolution in Greek patients with inflammatory bowel disease. BMC Gastroenterology, 2006, 6, 21.	2.0	23
85	Review article: should we treat symptoms or lesions in Crohn's disease? The case for treating symptoms. Alimentary Pharmacology and Therapeutics, 2006, 24, 33-36.	3.7	45
86	Review article: altering the natural history of Crohn's disease ? evidence for and against current therapies. Alimentary Pharmacology and Therapeutics, 2006, 25, 061016063002002-???	3.7	101
87	Inflammatory Bowel Disease: Pandora's Box, Present and Future. Annals of the New York Academy of Sciences, 2006, 1072, 365-378.	3.8	17
88	Isolated Ileal Erosions in Patients With Mildly Altered Bowel Habits. American Journal of Clinical Pathology, 2006, 125, 838-846.	0.7	54
89	Hospitalization, Surgery, and Readmission Rates of IBD in Canada: A Population-Based Study. American Journal of Gastroenterology, 2006, 101, 110-118.	0.4	144
90	Utilization of Health-Care Resources by Patients With IBD in Manitoba: A Profile of Time Since Diagnosis. American Journal of Gastroenterology, 2007, 102, 1683-1691.	0.4	36
91	Treatment inferred disease severity in Crohn's disease: Evidence for a European gradient of disease course. Scandinavian Journal of Gastroenterology, 2007, 42, 333-344.	1.5	22
92	Medical Therapy for Crohn's Disease: Top-Down or Step-Up?. Digestive Diseases, 2007, 25, 260-266.	1.9	36
93	Medical Management of Crohn's Disease. Clinics in Colon and Rectal Surgery, 2007, 20, 269-281.	1.1	13
94	Fibrogenesis in Crohn's Disease. American Journal of Gastroenterology, 2007, 102, 439-448.	0.4	244
95	Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies. Expert Review of Gastroenterology and Hepatology, 2007, 1, 101-112.	3.0	5
96	Biological therapies in inflammatory bowel disease: top-down or bottom-up?. Current Opinion in Gastroenterology, 2007, 23, 395-399.	2.3	46
97	Health-Related Quality of Life During Natalizumab Maintenance Therapy for Crohn's Disease. American Journal of Gastroenterology, 2007, 102, 2737-2746.	0.4	48
98	Risk for Active Tuberculosis in Inflammatory Bowel Disease Patients. Clinical Gastroenterology and Hepatology, 2007, 5, 1070-1075.e1.	4.4	59

#	ARTICLE	IF	CITATIONS
99	Clinical course in Crohn's disease: Results of a five-year population-based follow-up study (the IBSEN) Tj ETQq0 0 0 regBT /Overlock 10 Tf	1.5	199
100	Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohn's disease patients: A project of the European Collaborative Study Group on Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2007, 13, 874-881.	1.9	22
101	Synchronous multifocal colorectal and kidney cancer in a patient with longstanding history of ulcerative colitis. Inflammatory Bowel Diseases, 2007, 13, 1186-1188.	1.9	0
102	Safety and effectiveness of long-term budesonide treatment in maintaining remission in patients with mild-to-moderate Crohn's disease. Inflammatory Bowel Diseases, 2007, 13, 1184-1186.	1.9	2
103	Strictureplasty vs resection in small bowel Crohn's disease: an evaluation of short-term outcomes and recurrence. Colorectal Disease, 2007, 9, 686-694.	1.4	68
104	Clinical manifestations of inflammatory bowel disease: East and West differences. Journal of Digestive Diseases, 2007, 8, 121-127.	1.5	79
105	Resource use in patients with Crohn's disease treated with infliximab. Alimentary Pharmacology and Therapeutics, 2007, 26, 1313-1323.	3.7	35
106	Early versus late surgery for ileo-caecal Crohn's disease. Alimentary Pharmacology and Therapeutics, 2007, 26, 1303-1312.	3.7	90
107	Infliximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Alimentary Pharmacology and Therapeutics, 2007, 26, 1509-1520.	3.7	74
108	Enteral nutrition in adult Crohn's disease: Present status and perspectives. Molecular Nutrition and Food Research, 2008, 52, 875-884.	3.3	16
109	Health care and cost of medication for inflammatory bowel disease in the Rhein-Main region, Germany: A multicenter, prospective, internet-based study. Inflammatory Bowel Diseases, 2008, 14, 53-60.	1.9	16
110	Noninvasive Ultrasound Elasticity Imaging (UEI) of Crohn's Disease: Animal Model. Ultrasound in Medicine and Biology, 2008, 34, 902-912.	1.5	96
111	How often and for how long are IBD patients expected to be sick, off work, or in hospital each year?. Inflammatory Bowel Diseases, 2008, 14, S48-S49.	1.9	7
112	Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease - modelling outcomes in active luminal and fistulizing disease in adults. Alimentary Pharmacology and Therapeutics, 2008, 28, 76-87.	3.7	73
113	Mild to Moderate Crohn's Disease. Drugs, 2008, 68, 2419-2425.	10.9	8
114	The costs of Crohn's disease in the United States and other Western countries: a systematic review. Current Medical Research and Opinion, 2008, 24, 319-328.	1.9	165
115	Infliximab in Crohn's disease: early and long-term treatment. Digestive and Liver Disease, 2008, 40, S271-S279.	0.9	14
116	Intestinal fibrosis in inflammatory bowel disease - Current knowledge and future perspectives. Journal of Crohn's and Colitis, 2008, 2, 279-290.	1.3	130

#	ARTICLE	IF	CITATIONS
117	Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. <i>Clinical Therapeutics</i> , 2008, 30, 393-404.	2.5	145
118	How often and for how long are IBD patients expected to be sick, off work, or in hospital each year?. <i>Inflammatory Bowel Diseases</i> , 2008, 14, S48-S49.	1.9	2
120	How expensive is inflammatory bowel disease? A critical analysis. <i>World Journal of Gastroenterology</i> , 2008, 14, 6641.	3.3	57
121	Infliximab: A Review of its Use in the Treatment of Crohn's Disease. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S2250.	0.1	0
122	Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease. <i>American Journal of Gastroenterology</i> , 2009, 104, 2524-2533.	0.4	188
123	Appropriateness of colonoscopy in Europe (EPAGE II) – Chronic diarrhea and known inflammatory bowel disease. <i>Endoscopy</i> , 2009, 41, 218-226.	1.8	27
124	Crohn's disease in a southern European country: Montreal classification and clinical activity. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1343-1350.	1.9	22
125	Resource use and societal costs for Crohn's disease in Sweden. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1882-1890.	1.9	31
126	Intestinal Surgery for Crohn's Disease: Predictors of Recovery, Quality of Life, and Costs. <i>Journal of Gastrointestinal Surgery</i> , 2009, 13, 2128-2135.	1.7	23
127	Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 265-274.	3.7	111
128	Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 735-744.	3.7	19
129	Intestinal fibrosis in IBD – a dynamic, multifactorial process. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2009, 6, 228-235.	17.8	271
130	Clinical course of Crohn's disease first diagnosed at surgery for acute abdomen. <i>Digestive and Liver Disease</i> , 2009, 41, 269-276.	0.9	45
131	Effective dilation of small-bowel strictures by double-balloon enteroscopy in patients with symptomatic Crohn's disease (with video). <i>Gastrointestinal Endoscopy</i> , 2009, 70, 1030-1036.	1.0	121
132	Treatment of even mild to moderate Crohn's disease is a long-term challenge due to its remitting and relapsing course. <i>Drugs and Therapy Perspectives</i> , 2009, 25, 10-12.	0.6	0
133	Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohn's Disease. <i>Pharmacoeconomics</i> , 2009, 27, 609-621.	3.3	40
134	Management of Crohn's Disease in Adults. <i>American Journal of Gastroenterology</i> , 2009, 104, 465-483.	0.4	883
135	Safety Profile of IBD Therapeutics: Infectious Risks. <i>Gastroenterology Clinics of North America</i> , 2009, 38, 691-709.	2.2	36

#	ARTICLE	IF	CITATIONS
136	Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up. Gastroenterology Clinics of North America, 2009, 38, 577-594.	2.2	22
137	Prevalence and Outcome of Anemia After Restorative Proctocolectomy. Diseases of the Colon and Rectum, 2009, 52, 726-739.	1.3	32
138	Infliximab Maintenance Therapy Is Associated With Decreases in Direct Resource Use in Patients With Luminal or Fistulizing Crohn's Disease. Journal of Clinical Gastroenterology, 2009, 43, 950-956.	2.2	20
139	Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease. European Journal of Gastroenterology and Hepatology, 2009, 21, 1302-1309.	1.6	32
140	Fibrosis in the GI Tract: Pathophysiology, Diagnosis and Treatment Options. Frontiers of Gastrointestinal Research, 2009, , 15-31.	0.1	5
141	Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update. European Journal of Gastroenterology and Hepatology, 2010, 22, 779-786.	1.6	13
142	Scheduled Maintenance Therapy with Infliximab Improves the Prognosis of Crohn's Disease: A Single Center Prospective Cohort Study in Japan. Tohoku Journal of Experimental Medicine, 2010, 220, 207-215.	1.2	2
143	Validation of the Spanish version of a questionnaire to measure quality of care through the eyes of patients with inflammatory bowel disease (QUOTE-IBD). Inflammatory Bowel Diseases, 2010, 16, 982-992.	1.9	14
144	Adalimumab for Crohn's disease in clinical practice at Mayo clinic: The first 118 patients. Inflammatory Bowel Diseases, 2010, 16, 1912-1921.	1.9	45
145	Adverse effects of biologics used for treating IBD. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 167-182.	2.4	175
146	Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECISE 2 study. Alimentary Pharmacology and Therapeutics, 2010, 31, 1276-1285.	3.7	42
147	A claims-based Markov model for Crohn's disease. Alimentary Pharmacology and Therapeutics, 2010, 32, 448-458.	3.7	18
148	Adverse clinical phenotype in inflammatory bowel disease: A cross sectional study identifying factors potentially amenable to change. Journal of Gastroenterology and Hepatology (Australia), 2010, 25, 1250-1258.	2.8	33
150	A Maximum Likelihood Estimator of a Markov Model for Disease Activity in Crohn's Disease and Ulcerative Colitis for Annually Aggregated Partial Observations. Medical Decision Making, 2010, 30, 132-142.	2.4	8
151	The pharmacoeconomics of biologic therapy for IBD. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 103-109.	17.8	24
153	Recurrence and Impact of Postoperative Prophylaxis in Laparoscopically Treated Primary Ileocolic Crohn Disease. Archives of Surgery, 2010, 145, 42-7.	2.2	25
154	What is the optimal therapy for Crohn's disease: step-up or top-down?. Expert Review of Gastroenterology and Hepatology, 2010, 4, 167-180.	3.0	36
155	Evolving Inflammatory Bowel Disease Treatment Paradigms: Top-Down Versus Step-Up. Medical Clinics of North America, 2010, 94, 1-18.	2.5	33

#	ARTICLE	IF	CITATIONS
156	Clinical practice in Crohn's disease in bordering regions of two countries: Different medical options, distinct surgical events. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 301-311.	1.3	6
157	5-Aminosalicylic acid dependency in Crohn's disease: A Danish Crohn Colitis Database study. <i>Journal of Crohn's and Colitis</i> , 2010, 4, 575-581.	1.3	23
158	PGI26 CANADIAN COST-UTILITY ANALYSIS OF INITIATION AND MAINTENANCE TREATMENT WITH ANTI-TNF DRUGS FOR REFRACTORY CROHN'S DISEASE. <i>Value in Health</i> , 2010, 13, A73.	0.3	0
159	Safety Profile of IBD Therapeutics: Infectious Risks. <i>Medical Clinics of North America</i> , 2010, 94, 115-133.	2.5	18
160	The potential for disease modification in Crohn's disease. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 79-85.	17.8	80
161	The Natural History of Adult Crohn's Disease in Population-Based Cohorts. <i>American Journal of Gastroenterology</i> , 2010, 105, 289-297.	0.4	810
162	Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis. <i>American Journal of Gastroenterology</i> , 2011, 106, 2009-2017.	0.4	44
163	A framework for evidence-based health care incentives simulation. , 2011, , .		1
164	In favour of early surgery in Crohn's disease: A hypothesis to be tested. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 1-4.	1.3	27
165	Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 301-316.	1.3	33
166	Cost Effectiveness of Treatments for Inflammatory Bowel Disease. <i>Pharmacoeconomics</i> , 2011, 29, 387-401.	3.3	34
167	Current perspectives on <i>Mycobacterium avium</i> subsp. <i>paratuberculosis</i> , <i>Johne's</i> disease, and Crohn's disease: a Review. <i>Critical Reviews in Microbiology</i> , 2011, 37, 141-156.	6.1	72
169	CCR3 Blockade Attenuates Eosinophilic Ileitis and Associated Remodeling. <i>American Journal of Pathology</i> , 2011, 179, 2302-2314.	3.8	38
170	Markov model projection of remission status for early vs. delayed step-up adalimumab use in moderate to severe Crohn's disease.. <i>Inflammatory Bowel Diseases</i> , 2011, 17, S52-S53.	1.9	0
171	Treatment costs for the group of patients with non-specific inflammatory bowel disease during acute exacerbation and further annual observation. <i>Przegląd Gastroenterologiczny</i> , 2011, 1, 36-44.	0.7	1
172	Markov model projection of remission status for early versus delayed step-up adalimumab use in moderate to severe crohn's disease. <i>Gut</i> , 2011, 60, A137-A137.	12.1	1
173	Systematic review: the role of tacrolimus in the management of Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 1282-1294.	3.7	53
174	Hospitalization and surgical rates in patients with Crohn's disease treated with infliximab: a matched analysis. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 838-848.	1.9	27

#	ARTICLE	IF	CITATIONS
175	Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 1603-1609.	1.9	110
177	Practical application of anti-TNF therapy for luminal Crohn's disease. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 2366-2391.	1.9	18
179	Current and future role of biomarkers in Crohn's disease risk assessment and treatment. <i>Clinical and Experimental Gastroenterology</i> , 2011, 4, 127.	2.3	16
180	Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. <i>Gut</i> , 2011, 60, 1754-1763.	12.1	110
181	Factors affecting outcomes in Crohn's disease over 15 years. <i>Gut</i> , 2012, 61, 1140-1145.	12.1	108
183	Patient Adherence and Efficacy of Certolizumab Pegol in the Management of Crohn's Disease. <i>Clinical Medicine Insights Gastroenterology</i> , 2012, 5, CGast.S7613.	1.0	2
184	Hospitalisations and surgery in Crohn's disease. <i>Gut</i> , 2012, 61, 622-629.	12.1	244
185	New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. <i>Gut</i> , 2012, 61, i36-i46.	12.1	168
187	Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF drugs for refractory Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 77-85.	1.3	29
188	Inflammatory Bowel Disease: A Canadian Burden of Illness Review. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2012, 26, 811-817.	1.7	229
189	Burden of Crohn's disease: economics and quality of life aspects in Italy. <i>ClinicoEconomics and Outcomes Research</i> , 2012, 4, 209.	1.9	13
190	Direct Medical Cost of Managing IBD Patients: A Canadian Population-based Study. <i>Inflammatory Bowel Diseases</i> , 2012, 18, 1498-1508.	1.9	71
191	Cost-Utility Analysis of Biologic Treatments for Moderate-to-Severe Crohn's Disease. <i>Pharmacotherapy</i> , 2012, 32, 515-526.	2.6	27
192	¹⁸ F-FDG positron emission tomography: potential utility in the assessment of Crohn's disease. <i>Abdominal Imaging</i> , 2012, 37, 377-386.	2.0	18
193	Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn's Disease: Results of a Decision Analysis. <i>Digestive Diseases and Sciences</i> , 2012, 57, 472-480.	2.3	18
194	Predictive factors for an uncomplicated long-term course of Crohn's disease: A retrospective analysis. <i>Journal of Crohn's and Colitis</i> , 2013, 7, e263-e270.	1.3	27
195	Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. <i>European Journal of Health Economics</i> , 2013, 14, 853-861.	2.8	40
196	Health Care Costs of Complex Perianal Fistula in Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2013, 58, 3400-3406.	2.3	38

#	ARTICLE	IF	CITATIONS
197	A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 654-666.	4.4	168
198	Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2013, 37, 438-444.	3.7	37
199	Inflammatory Bowel Disease: An Expanding Global Health Problem. <i>Clinical Medicine Insights Gastroenterology</i> , 2013, 6, CGast.S12731.	1.0	237
200	Cost-effectiveness of Nonmelanoma Skin Cancer Screening in Crohn's Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 2787-2795.	1.9	9
201	Biological therapies in Crohn's disease: are they cost-effective? A critical appraisal of model-based analyses. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 815-824.	1.4	39
202	Impact of balloon-assisted enteroscopy on the diagnosis and management of suspected and established small-bowel Crohn's disease. <i>Endoscopy International Open</i> , 2014, 02, E201-E206.	1.8	20
203	Description and prediction of the development of metabolic syndrome in Dongying City: a longitudinal analysis using the Markov model. <i>BMC Public Health</i> , 2014, 14, 1033.	2.9	14
204	The Impact of Moderate-to-severe Crohn's Disease on Employees' Salary Growth. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 1734-1738.	1.9	4
205	Effect of Aging on Healthcare Costs of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 637-645.	1.9	15
206	Understanding Proximal-Distal Economic Projections of the Benefits of Childhood Preventive Interventions. <i>Prevention Science</i> , 2014, 15, 807-817.	2.6	4
207	Challenges in Designing a National Surveillance Program for Inflammatory Bowel Disease in the United States. <i>Inflammatory Bowel Diseases</i> , 2014, 20, 398-415.	1.9	33
208	When and How to Stop Anti-TNF Treatment in Inflammatory Bowel Disease: Predictors of Relapse after Stopping Treatment. <i>Frontiers of Gastrointestinal Research</i> , 0, , 224-228.	0.1	0
209	Predictors of ICU Admission and Outcomes 1 Year Post-Admission in Persons with IBD. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1.	1.9	4
210	Economic implications of biological therapy for Crohn's disease. <i>Przegląd Gastroenterologiczny</i> , 2015, 4, 197-202.	0.7	2
211	Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database. <i>Current Medical Research and Opinion</i> , 2015, 31, 1655-1664.	1.9	31
212	Health Care Cost Analysis in a Population-based Inception Cohort of Inflammatory Bowel Disease Patients in the First Year of Diagnosis. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 988-996.	1.3	40
213	The epidemiology of inflammatory bowel disease. <i>Scandinavian Journal of Gastroenterology</i> , 2015, 50, 942-951.	1.5	272
214	Homocysteine Promotes Intestinal Fibrosis in Rats with Trinitrobenzene Sulfonic Acid-Induced Colitis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 375-381.	2.3	12

#	ARTICLE	IF	CITATIONS
215	Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 747-753.	1.3	38
217	Higher Levels of Knowledge Reduce Health Care Costs in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 615-622.	1.9	53
218	Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 121-131.	1.9	47
219	Medical Therapy of Fibrostenotic Crohn's Disease. <i>Visceral Medicine</i> , 2015, 31, 259-264.	1.3	2
220	Precision-cut rat, mouse, and human intestinal slices as novel models for the early-onset of intestinal fibrosis. <i>Physiological Reports</i> , 2015, 3, e12323.	1.7	19
221	Cost-effectiveness of Prophylaxis Against <i>Pneumocystis jiroveci</i> Pneumonia in Patients with Crohn's Disease. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3743-3755.	2.3	14
222	Costs in inflammatory bowel diseases. <i>Przegląd Gastroenterologiczny</i> , 2016, 1, 6-13.	0.7	22
223	Demographic and Clinical Predictors of High Healthcare Use in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1442-1449.	1.9	72
224	Clinical predictors of Crohn's disease course. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 1122-1125.	1.6	11
225	Group-Based Trajectory Modeling of Healthcare Financial Charges in Inflammatory Bowel Disease: A Comprehensive Phenotype. <i>Clinical and Translational Gastroenterology</i> , 2016, 7, e181.	2.5	14
226	Costs of Crohn's Disease According to Severity States in France. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2924-2932.	1.9	6
227	Rates and Reasons for Nonuse of Prescription Medication for Inflammatory Bowel Disease in a Referral Clinic. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 919-924.	1.9	11
228	Inflammatory Bowel Disease Patients' Participation, Attitude and Preferences Toward Exercise. <i>International Journal of Sports Medicine</i> , 2016, 37, 665-670.	1.7	6
229	Course of Crohn's Disease. , 2016, , 31-42.		0
230	<sc>A</sc>iaâ€“<sc>P</sc>acific consensus statements on <sc>C</sc>rohn's disease. Part 2: Management. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 56-68.	2.8	42
231	Top-down approach to biological therapy of Crohn's disease. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 285-293.	3.1	11
232	Evaluation of Health Economics in Inflammatory Bowel Disease. , 2017, , 291-297.		0
233	The Natural History of Inflammatory Bowel Disease. , 2017, , 301-309.		0

#	ARTICLE	IF	CITATIONS
234	Impact of Early Surgery and Immunosuppression on Crohn's Disease Disabling Outcomes. Inflammatory Bowel Diseases, 2017, 23, 289-297.	1.9	17
235	Tuberculosis in China: a longitudinal predictive model of the general population and recommendations for achieving WHO goals. Respiriology, 2017, 22, 1423-1429.	2.3	12
236	White Paper AGA: The Impact of Mental and Psychosocial Factors on the Care of Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2017, 15, 986-997.	4.4	83
237	Improvements in the Long-Term Outcome of Crohn's Disease Over the Past Two Decades and the Relation to Changes in Medical Management: Results from the Population-Based IBDSC Cohort. American Journal of Gastroenterology, 2017, 112, 325-336.	0.4	127
238	Predicting Costs of Care for Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2017, 15, 393-395.	4.4	10
239	Crohn Disease. Clinical Nuclear Medicine, 2017, 42, 837-841.	1.3	8
240	Epidemiology, Natural History, and Risk Stratification of Crohn's Disease. Gastroenterology Clinics of North America, 2017, 46, 463-480.	2.2	78
241	Short- and medium-term outcomes following primary ileocaecal resection for Crohn's disease in two specialist centres. British Journal of Surgery, 2017, 104, 1713-1722.	0.3	91
242	The Cost of Crohn's Disease. Inflammatory Bowel Diseases, 2017, 23, 107-115.	1.9	24
244	Factors associated with readmission to the hospital within 30 days in patients with inflammatory bowel disease. PLoS ONE, 2017, 12, e0182900.	2.5	39
245	Postoperative course of Crohn disease according to timing of bowel resection. Medicine (United States), 2017, 96, 107-115.	1.0	20
246	Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor- α Antagonist. Pharmacoeconomics, 2018, 36, 853-865.	3.3	14
247	ACG Clinical Guideline: Management of Crohn's Disease in Adults. American Journal of Gastroenterology, 2018, 113, 481-517.	0.4	851
248	Telephone Encounters Predict Future High Financial Expenditures in Inflammatory Bowel Disease Patients. Journal of Clinical Gastroenterology, 2018, 52, 319-325.	2.2	3
249	Ultrasound Elasticity Imaging Predicts Therapeutic Outcomes of Patients With Crohn's Disease Treated With Anti-Tumour Necrosis Factor Antibodies. Journal of Crohn's and Colitis, 2018, 12, 63-70.	1.3	56
250	A comprehensive review and update on Crohn's disease. Disease-a-Month, 2018, 64, 20-57.	1.1	318
251	Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden. Cost Effectiveness and Resource Allocation, 2018, 16, 28.	1.5	4
252	Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 114-126.	3.7	12

#	ARTICLE	IF	CITATIONS
253	Physiciansâ€™ Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohnâ€™s Disease. Digestive Diseases and Sciences, 2018, 63, 2555-2563.	2.3	12
254	Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohnâ€™s Disease. Pharmacoeconomics, 2019, 37, 1509-1523.	3.3	7
255	Herbs-Partitioned Moxibustion Combined with Acupuncture Inhibits TGF- β 1-Smad-Snail-Induced Intestinal Epithelial Mesenchymal Transition in Crohnâ€™s Disease Model Rats. Evidence-based Complementary and Alternative Medicine, 2019, 2019, 1-9.	1.2	7
256	The Cost-effectiveness of Initial Immunomodulators or Infliximab Using Modern Optimization Strategies for Crohnâ€™s Disease in the Biosimilar Era. Inflammatory Bowel Diseases, 2020, 26, 369-379.	1.9	7
257	Systematic Review: Cost-effective Strategies of Optimizing Anti-tumor Necrosis and Immunomodulators in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1462-1473.	1.9	15
258	Predictive factors for exacerbation and re-exacerbation in chronic obstructive pulmonary disease: an extension of the Cox model to analyze data from the Swiss COPD cohort. Multidisciplinary Respiratory Medicine, 2019, 14, 7.	1.5	11
259	Assessment of Patientsâ€™ Future Outlook after Bowel Resection in Crohnâ€™s Disease. Gastroenterology Research and Practice, 2019, 2019, 1-7.	1.5	1
260	Pathogenesis of fibrostenosing Crohn's disease. Translational Research, 2019, 209, 39-54.	5.0	60
261	Simulating the Risk of Stroke in China Using Markov Model Based on National Screening Data. , 2019, , .		2
262	A novel surgical predictive model for Chinese Crohn's disease patients. Medicine (United States), 2019, 98, e17510.	1.0	16
263	Intestinal fibrosis. Molecular Aspects of Medicine, 2019, 65, 100-109.	6.4	77
264	Developing a core outcome set for fistulising perianal Crohnâ€™s disease. Gut, 2019, 68, 226-238.	12.1	64
265	Proactive Vs Reactive Therapeutic Drug Monitoring of Infliximab in Crohnâ€™s Disease: A Cost-Effectiveness Analysis in a Simulated Cohort. Inflammatory Bowel Diseases, 2020, 26, 103-111.	1.9	34
266	Lifetime Economic Burden of Crohnâ€™s Disease and Ulcerative Colitis by Age at Diagnosis. Clinical Gastroenterology and Hepatology, 2020, 18, 889-897.e10.	4.4	53
268	Meta-analysis of early bowel resection versus initial medical therapy in patient's with ileocolonic Crohn's disease. International Journal of Colorectal Disease, 2020, 35, 501-512.	2.2	4
269	Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohnâ€™s disease using real world evidence in Thailand. Journal of Medical Economics, 2020, 23, 1302-1310.	2.1	3
270	Betulinic acid hydroxamate prevents colonic inflammation and fibrosis in murine models of inflammatory bowel disease. Acta Pharmacologica Sinica, 2021, 42, 1124-1138.	6.1	21
271	Role of non-inflammatory factors in intestinal fibrosis. Journal of Digestive Diseases, 2020, 21, 315-318.	1.5	8

#	ARTICLE	IF	CITATIONS
272	Decrease in primary but not in secondary abdominal surgery for Crohn's disease: nationwide cohort study, 1990–2014. British Journal of Surgery, 2020, 107, 1529-1538.	0.3	38
273	Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. Gut, 2020, 69, 658-664.	12.1	21
274	Strictureplasty versus bowel resection for the surgical management of fibrostenotic Crohn's disease: a systematic review and meta-analysis. International Journal of Colorectal Disease, 2020, 35, 705-717.	2.2	14
275	Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. The Lancet Gastroenterology and Hepatology, 2020, 5, 454-464.	8.1	76
276	Therapeutic resolution of focal, predominantly anastomotic Crohn's disease strictures using removable stents: outcomes from a single-center case series in the United Kingdom. Gastrointestinal Endoscopy, 2020, 92, 344-352.	1.0	25
277	A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn's Disease. Journal of the Canadian Association of Gastroenterology, 2021, 4, 48-48.	0.3	8
278	Proactive therapeutic drug monitoring of adalimumab for pediatric Crohn's disease patients: A cost-effectiveness analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 2397-2407.	2.8	10
279	Pharmacoeconomical Impacts of Crohn's Disease. , 0, , .		0
280	Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study. Health Technology Assessment, 2021, 25, 1-138.	2.8	2
281	Crohn's disease: a population-based study of surgery in the age of biological therapy. International Journal of Colorectal Disease, 2021, 36, 2419-2426.	2.2	21
282	Stromal Cells Underlining the Paths From Autoimmunity, Inflammation to Cancer With Roles Beyond Structural and Nutritional Support. Frontiers in Cell and Developmental Biology, 2021, 9, 658984.	3.7	8
283	Long-term Disease Course of Crohn's Disease: Changes in Disease Location, Phenotype, Activities, and Predictive Factors. Gut and Liver, 2022, 16, 157-170.	2.9	8
284	The clinical course of Crohn's disease in a Danish population-based inception cohort with more than 50 years of follow-up, 1962–2017. Alimentary Pharmacology and Therapeutics, 2022, 55, 73-82.	3.7	11
285	Timing of surgery for enterovesical fistula in Crohn's disease: Decision analysis using a time-dependent compartment model. Inflammatory Bowel Diseases, 2000, 6, 280-285.	1.9	7
287	The New Economic Reality in the World of IBD. , 2011, , 295-313.		1
288	The Burden of Cost in Inflammatory Bowel Disease: A Medical Economic Perspective and the Future of Value-Based Care. Current Gastroenterology Reports, 2020, 22, 6.	2.5	26
289	Crohn's Disease: Current Pathogenetic Paradigms. , 2005, , 1265-1285.		4
291	Management of Crohn's disease in adults. American Journal of Gastroenterology, 2001, 96, 635-643.	0.4	258

#	ARTICLE	IF	CITATIONS
292	Description and Prediction of the Development of Metabolic Syndrome: A Longitudinal Analysis Using a Markov Model Approach. PLoS ONE, 2013, 8, e67436.	2.5	21
293	A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. ClinicoEconomics and Outcomes Research, 2014, 6, 431.	1.9	13
294	Anti-TNF and Crohns Disease: When Should We Stop?. Current Drug Targets, 2010, 11, 148-151.	2.1	14
295	Immunomodulators: Friends or Enemies in Surgery for Crohn's Disease?. Current Drug Targets, 2019, 20, 1384-1398.	2.1	4
296	A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF- α) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technology Assessment, 2011, 15, 1-244.	2.8	105
297	Clinical effectiveness and cost-effectiveness of use of therapeutic monitoring of tumour necrosis factor alpha (TNF- α) inhibitors [LISA-TRACKER [®] enzyme-linked immunosorbent assay (ELISA) kits, TNF- α -Blocker ELISA kits and Promonitor [®] ELISA kits] versus standard care in patients with Crohn's disease: systematic reviews and economic modelling. Health Technology Assessment, 2016, 20, 1-288.	2.8	27
298	Role of conventional therapies in the era of biological treatment in Crohn's disease. World Journal of Gastroenterology, 2011, 17, 1797.	3.3	11
299	Crucial steps in the natural history of inflammatory bowel disease. World Journal of Gastroenterology, 2012, 18, 3790.	3.3	94
300	Impact of medical therapy on patients with Crohn's disease requiring surgical resection. World Journal of Gastroenterology, 2014, 20, 11808.	3.3	7
301	Cost-effectiveness of Crohn's disease post-operative care. World Journal of Gastroenterology, 2016, 22, 3860.	3.3	9
302	Early surgery in Crohn's disease a benefit in selected cases. World Journal of Gastrointestinal Surgery, 2016, 8, 492.	1.5	29
303	Clinical features and complications of Crohn's disease. , 2003, , 291-304.		0
304	Pharmacoeconomics and inflammatory bowel disease. , 2003, , 471-480.		0
305	Clinical Presentation. , 2010, , 43-51.		0
306	Histoire naturelle de la maladie de Crohn. , 2011, , 105-114.		0
308	What If I Do Not Get Myself Treated for Crohn's Disease? Natural History of Crohn's Disease. , 2015, , 35-39.		0
309	Unusual Cause of Colonic Obstruction: A Case Report. Gastroenterology & Hepatology (Bartlesville,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.1	0
310	The changing landscape of surgery for Crohn's disease. Seminars in Colon and Rectal Surgery, 2020, 31, 100740.	0.3	0

#	ARTICLE	IF	CITATIONS
311	How do I use steroids in Crohn's disease?. , 0, , 111-119.		0
312	Predicting the natural history of inflammatory bowel disease. , 0, , 63-69.		0
313	Indications for use of infliximab in inflammatory bowel disease. , 0, , 165-182.		0
314	Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, 28, 337-349.	1.9	20
316	Analyzing hospital costs for patients with inflammatory bowel disease. American Journal of Gastroenterology, 2000, 95, 577-578.	0.4	1
317	Patients With Stricturing or Penetrating Crohn's Disease Phenotypes Report High Disease Burden and Treatment Needs. Inflammatory Bowel Diseases, 2023, 29, 914-922.	1.9	2
318	Cost-effectiveness Analysis of Subcutaneous Infliximab for Inflammatory Bowel Diseases in Sequential Biologic Treatment. Inflammatory Bowel Diseases, 2023, 29, 898-913.	1.9	2
319	Mobile Apps for the Management of Gastrointestinal Diseases: Systematic Search and Evaluation Within App Stores. Journal of Medical Internet Research, 2022, 24, e37497.	4.3	3
320	Disease course and treatment outcomes of Crohn's disease patients with early or late surgery â€” A Danish nationwide cohort study from 1997 to 2015. Digestive and Liver Disease, 2023, 55, 872-879.	0.9	3
322	Molecular Basis of Intestinal Fibrosis in Inflammatory Bowel Disease. Inflammatory Intestinal Diseases, 2022, 7, 119-127.	1.9	3
323	Natural compound fraxinellone ameliorates intestinal fibrosis in mice via direct intervention of HSP47-collagen interaction in the epithelium. Acta Pharmacologica Sinica, 0, , .	6.1	1
326	Research Agenda for Pediatric Gastroenterology, Hepatology and Nutrition: Secretion and Diarrhea: Report of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition for the Children's Digestive Health and Nutrition Foundation. Journal of Pediatric Gastroenterology and Nutrition, 2002, 35, .	1.8	0